Acute upper gastrointestinal bleeding in over 16s: management

New evidence

We found 9 new studies in a search for randomised controlled trials and systematic reviews published between 20 February 2014 and 6 April 2016.

Evidence from 9 studies identified in an evidence update published 2 years after publication of the guideline was also considered.

From all sources, 18 studies were considered to be relevant to the guideline.

We also checked for relevant ongoing research, which will be evaluated again at the next surveillance review of the guideline.

See appendix A: summary of new evidence from surveillance and references for all new evidence considered.

Views of topic experts

We considered the views of topic experts, including those who helped to develop the guideline and other correspondence we have received since the publication of the guideline.

Views of stakeholders

Stakeholders commented on the decision not to update the guideline. Overall, three stakeholders commented. See appendix B for stakeholders' comments and our responses.

Three stakeholders commented on the proposal to not update the guideline and all 3 agreed with the decision. Stakeholders also highlighted for future surveillance the ongoing HALT-IT trial on tranexamic acid. This study will be monitored in the surveillance trial tracker and considered when results become available.

Overall, we decided not to update the guideline.

See ensuring that published guidelines are current and accurate in 'Developing NICE guidelines: the manual' for more details on our consultation processes.

NICE Surveillance programme project team

Sarah Willett
Associate Director

Philip Alderson
Consultant Clinical Adviser

Emma McFarlane
Technical Adviser

Omar Moreea
Technical Analyst

The NICE project team would like to thank the topic experts who participated in the surveillance process.